CL2008002564A1 - Un compuesto (6ar,10ar)-7-n-propil-6,6a,7,8,9,10,10a,11-octahidro-1,3-dioxa-7-aza-ciclopenta[a]antraceno o una sal de adicion de acido del mismo; composicion farmaceutica; y su uso en el tratamiento de trastornos degenerativos tales como la enfermedad de parkinson y la de huntington, tratamiento de psicosis, impotencia, insuficiencia renal, entre otras enfermedades. - Google Patents
Un compuesto (6ar,10ar)-7-n-propil-6,6a,7,8,9,10,10a,11-octahidro-1,3-dioxa-7-aza-ciclopenta[a]antraceno o una sal de adicion de acido del mismo; composicion farmaceutica; y su uso en el tratamiento de trastornos degenerativos tales como la enfermedad de parkinson y la de huntington, tratamiento de psicosis, impotencia, insuficiencia renal, entre otras enfermedades.Info
- Publication number
- CL2008002564A1 CL2008002564A1 CL2008002564A CL2008002564A CL2008002564A1 CL 2008002564 A1 CL2008002564 A1 CL 2008002564A1 CL 2008002564 A CL2008002564 A CL 2008002564A CL 2008002564 A CL2008002564 A CL 2008002564A CL 2008002564 A1 CL2008002564 A1 CL 2008002564A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- compound
- pharmaceutical composition
- salt
- impotence
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- DKFJCEPDDQVHLK-UKRRQHHQSA-N (6ar,10ar)-7-propyl-6a,8,9,10,10a,11-hexahydro-6h-[1,3]benzodioxolo[7,6-g]quinoline Chemical compound C1=C2C[C@H]3N(CCC)CCC[C@@H]3CC2=C2OCOC2=C1 DKFJCEPDDQVHLK-UKRRQHHQSA-N 0.000 title 1
- 208000023105 Huntington disease Diseases 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 title 1
- 208000001647 Renal Insufficiency Diseases 0.000 title 1
- 230000003412 degenerative effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 201000001881 impotence Diseases 0.000 title 1
- 201000006370 kidney failure Diseases 0.000 title 1
- 239000000969 carrier Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/08—Aza-anthracenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Portable Nailing Machines And Staplers (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200701250 | 2007-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008002564A1 true CL2008002564A1 (es) | 2009-07-17 |
Family
ID=39877715
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008002564A CL2008002564A1 (es) | 2007-08-31 | 2008-08-29 | Un compuesto (6ar,10ar)-7-n-propil-6,6a,7,8,9,10,10a,11-octahidro-1,3-dioxa-7-aza-ciclopenta[a]antraceno o una sal de adicion de acido del mismo; composicion farmaceutica; y su uso en el tratamiento de trastornos degenerativos tales como la enfermedad de parkinson y la de huntington, tratamiento de psicosis, impotencia, insuficiencia renal, entre otras enfermedades. |
| CL2008002558A CL2008002558A1 (es) | 2007-08-31 | 2008-08-29 | Compuestos derivados de catecolamina sustituidas, composicion farmaceutica, util para tratar parkinson, huntington, psicosis, impotencia e insuficiencia renal, entre otras enfermedades. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008002558A CL2008002558A1 (es) | 2007-08-31 | 2008-08-29 | Compuestos derivados de catecolamina sustituidas, composicion farmaceutica, util para tratar parkinson, huntington, psicosis, impotencia e insuficiencia renal, entre otras enfermedades. |
Country Status (29)
| Country | Link |
|---|---|
| EP (4) | EP3009437A1 (enExample) |
| JP (4) | JP2010536890A (enExample) |
| KR (3) | KR20150115963A (enExample) |
| CN (3) | CN107253956A (enExample) |
| AR (2) | AR068044A1 (enExample) |
| AU (2) | AU2008291425B2 (enExample) |
| BR (2) | BRPI0815894A2 (enExample) |
| CA (2) | CA2691961C (enExample) |
| CL (2) | CL2008002564A1 (enExample) |
| CO (2) | CO6270232A2 (enExample) |
| CY (1) | CY1117326T1 (enExample) |
| DK (1) | DK2197883T3 (enExample) |
| EA (2) | EA018413B1 (enExample) |
| ES (1) | ES2557485T3 (enExample) |
| HR (1) | HRP20151334T1 (enExample) |
| HU (1) | HUE025882T2 (enExample) |
| IL (1) | IL203080A (enExample) |
| MX (1) | MX2010002210A (enExample) |
| MY (2) | MY179527A (enExample) |
| NZ (2) | NZ582379A (enExample) |
| PL (1) | PL2197883T3 (enExample) |
| PT (1) | PT2197883E (enExample) |
| RS (1) | RS54470B1 (enExample) |
| SG (1) | SG184711A1 (enExample) |
| SI (1) | SI2197883T1 (enExample) |
| TW (2) | TWI404702B (enExample) |
| UA (2) | UA98804C2 (enExample) |
| WO (2) | WO2009026935A1 (enExample) |
| ZA (2) | ZA200909191B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI404702B (zh) * | 2007-08-31 | 2013-08-11 | Lundbeck & Co As H | 兒茶酚胺衍生物和其前藥 |
| JP2011525893A (ja) * | 2008-06-27 | 2011-09-29 | ハー・ルンドベック・アクチエゼルスカベット | 新規のフェノールアミン類およびカテコールアミン類ならびにそのプロドラッグ |
| US8067410B2 (en) | 2008-06-27 | 2011-11-29 | H. Lundbeck A/S | Phenolic and catecholic amines and prodrugs thereof |
| TW201036949A (en) * | 2009-02-27 | 2010-10-16 | Lundbeck & Co As H | Treatment of dyskinesia related disorders |
| TW201035054A (en) * | 2009-02-27 | 2010-10-01 | Lundbeck & Co As H | Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof |
| MA50800A (fr) * | 2017-11-24 | 2020-09-30 | H Lundbeck As | Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson |
| WO2020070099A1 (en) | 2018-10-02 | 2020-04-09 | H. Lundbeck A/S | Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist |
| US11111263B2 (en) * | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11168056B2 (en) * | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| EP3972970A1 (en) * | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| EP3972959A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| WO2020234275A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
| US12398106B2 (en) | 2019-05-21 | 2025-08-26 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson's disease |
| CN114478298B (zh) * | 2020-11-12 | 2024-09-27 | 成都西岭源药业有限公司 | 一种造影剂碘佛醇的纯化方法 |
| CN116568672A (zh) * | 2020-11-17 | 2023-08-08 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
| CN113620760A (zh) * | 2021-09-07 | 2021-11-09 | 张家口思睿凯科技有限公司 | 一种电子盐反应液和不饱和芳香烃类化合物的还原方法 |
| WO2025078574A1 (en) * | 2023-10-12 | 2025-04-17 | Integrative Research Laboratories Sweden Ab | NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080456A (en) * | 1971-10-26 | 1978-03-21 | Schering Aktiengesellschaft | Diacylapomorphines |
| CH648300A5 (en) * | 1979-06-22 | 1985-03-15 | Sandoz Ag | Phenanthrene derivatives and medicaments containing them |
| US4543256A (en) * | 1982-03-17 | 1985-09-24 | Northeastern University | (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers |
| WO1990012574A1 (en) * | 1989-04-25 | 1990-11-01 | Northeastern University | Dopamine agonist compounds |
| RU2045528C1 (ru) * | 1989-08-30 | 1995-10-10 | Санкио Компани Лимитед | Способ получения оптически активного производного индолобензохинолина или его фармацевтически приемлемых солей |
| TW357143B (en) * | 1995-07-07 | 1999-05-01 | Novartis Ag | Benzo[g]quinoline derivatives |
| JPH11515030A (ja) * | 1995-11-10 | 1999-12-21 | ノボ ノルディスク アクティーゼルスカブ | シス−ベンズ［ｅ］インドール化合物のエナンチオマー、これらの製造、及びドーパミン−Ｄ３受容体選択的医薬としての利用 |
| CN1241998A (zh) * | 1996-10-30 | 2000-01-19 | 伊莱利利公司 | 苯并[f]喹啉酮的合成 |
| SE0002934D0 (sv) * | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
| SE0102036D0 (sv) | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
| AR030357A1 (es) * | 2000-08-18 | 2003-08-20 | Lundbeck & Co As H | Derivados 4 -, 5 -, 6 - y 7-indol |
| US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
| TWI404702B (zh) * | 2007-08-31 | 2013-08-11 | Lundbeck & Co As H | 兒茶酚胺衍生物和其前藥 |
-
2008
- 2008-08-19 TW TW097131506A patent/TWI404702B/zh not_active IP Right Cessation
- 2008-08-27 AR ARP080103713A patent/AR068044A1/es active IP Right Grant
- 2008-08-27 AR ARP080103714A patent/AR068045A1/es not_active Application Discontinuation
- 2008-08-28 KR KR1020157026863A patent/KR20150115963A/ko not_active Ceased
- 2008-08-28 CN CN201710269745.1A patent/CN107253956A/zh active Pending
- 2008-08-28 EP EP15188376.6A patent/EP3009437A1/en not_active Withdrawn
- 2008-08-28 SG SG2012064408A patent/SG184711A1/en unknown
- 2008-08-28 EA EA201070327A patent/EA018413B1/ru not_active IP Right Cessation
- 2008-08-28 CN CN200880113440A patent/CN101842354A/zh active Pending
- 2008-08-28 NZ NZ582379A patent/NZ582379A/en not_active IP Right Cessation
- 2008-08-28 WO PCT/DK2008/050215 patent/WO2009026935A1/en not_active Ceased
- 2008-08-28 DK DK08784472.6T patent/DK2197883T3/en active
- 2008-08-28 WO PCT/DK2008/050214 patent/WO2009026934A1/en not_active Ceased
- 2008-08-28 CA CA2691961A patent/CA2691961C/en active Active
- 2008-08-28 AU AU2008291425A patent/AU2008291425B2/en not_active Ceased
- 2008-08-28 KR KR1020107004461A patent/KR20100051834A/ko not_active Ceased
- 2008-08-28 UA UAA201003349A patent/UA98804C2/ru unknown
- 2008-08-28 NZ NZ583551A patent/NZ583551A/en not_active IP Right Cessation
- 2008-08-28 SI SI200831554T patent/SI2197883T1/sl unknown
- 2008-08-28 AU AU2008291426A patent/AU2008291426B2/en not_active Ceased
- 2008-08-28 EP EP08784473A patent/EP2195291A1/en not_active Withdrawn
- 2008-08-28 RS RS20150874A patent/RS54470B1/sr unknown
- 2008-08-28 JP JP2010522187A patent/JP2010536890A/ja active Pending
- 2008-08-28 JP JP2010522186A patent/JP5548125B2/ja not_active Expired - Fee Related
- 2008-08-28 EP EP13175011.9A patent/EP2662358A1/en not_active Withdrawn
- 2008-08-28 EA EA200971107A patent/EA018011B1/ru not_active IP Right Cessation
- 2008-08-28 HR HRP20151334TT patent/HRP20151334T1/hr unknown
- 2008-08-28 HU HUE08784472A patent/HUE025882T2/en unknown
- 2008-08-28 CA CA2697688A patent/CA2697688A1/en not_active Abandoned
- 2008-08-28 MY MYPI20095490A patent/MY179527A/en unknown
- 2008-08-28 ES ES08784472.6T patent/ES2557485T3/es active Active
- 2008-08-28 EP EP08784472.6A patent/EP2197883B1/en active Active
- 2008-08-28 PL PL08784472T patent/PL2197883T3/pl unknown
- 2008-08-28 MY MYPI2010000841A patent/MY148948A/en unknown
- 2008-08-28 PT PT87844726T patent/PT2197883E/pt unknown
- 2008-08-28 KR KR1020097027342A patent/KR101597367B1/ko not_active Expired - Fee Related
- 2008-08-28 BR BRPI0815894-0A2A patent/BRPI0815894A2/pt not_active IP Right Cessation
- 2008-08-28 CN CN200880023124A patent/CN101687878A/zh active Pending
- 2008-08-28 BR BRPI0813456-1A2A patent/BRPI0813456A2/pt not_active Application Discontinuation
- 2008-08-28 UA UAA201000849A patent/UA97989C2/uk unknown
- 2008-08-28 MX MX2010002210A patent/MX2010002210A/es active IP Right Grant
- 2008-08-29 CL CL2008002564A patent/CL2008002564A1/es unknown
- 2008-08-29 CL CL2008002558A patent/CL2008002558A1/es unknown
- 2008-08-29 TW TW097133076A patent/TW200914426A/zh unknown
-
2009
- 2009-12-23 ZA ZA2009/09191A patent/ZA200909191B/en unknown
- 2009-12-30 CO CO09149335A patent/CO6270232A2/es active IP Right Grant
- 2009-12-31 IL IL203080A patent/IL203080A/en active IP Right Grant
-
2010
- 2010-02-26 ZA ZA2010/01422A patent/ZA201001422B/en unknown
- 2010-02-26 CO CO10023455A patent/CO6260082A2/es active IP Right Grant
-
2014
- 2014-02-06 JP JP2014021193A patent/JP2014111635A/ja active Pending
- 2014-04-17 JP JP2014085192A patent/JP5802792B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-28 CY CY20151101191T patent/CY1117326T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008002564A1 (es) | Un compuesto (6ar,10ar)-7-n-propil-6,6a,7,8,9,10,10a,11-octahidro-1,3-dioxa-7-aza-ciclopenta[a]antraceno o una sal de adicion de acido del mismo; composicion farmaceutica; y su uso en el tratamiento de trastornos degenerativos tales como la enfermedad de parkinson y la de huntington, tratamiento de psicosis, impotencia, insuficiencia renal, entre otras enfermedades. | |
| AR071187A1 (es) | Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer | |
| DOP2014000085A (es) | Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio | |
| CL2011003302A1 (es) | Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros. | |
| UY31405A1 (es) | "piperidino-dihidrotienopirimidas sustituidas" | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| SV2010003497A (es) | Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis | |
| UY31430A1 (es) | Derivados de piridina y pirazina -83 | |
| CL2011003072A1 (es) | Compuestos derivados de 4´-(isoxazol-5-il)-bifenil-4-il-cicloalquil(c3-8), antagonistas del receptor de acido lisofosfatidico; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, problemas pulmonares, entre otras. | |
| CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
| MX347828B (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento. | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| AR085219A1 (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc | |
| AR075152A1 (es) | Preparacion y aplicaciones terapeuticas de (2s, 3r)-n-2-((3-piridinil)metil)-1-azabiciclo(2.2.2.)oct-3-il)-3,5-difluorobenzamida | |
| PE20141607A1 (es) | Compuestos heterociclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparacion | |
| PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
| ECSP11010956A (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| GT201500035A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
| MX2015011074A (es) | Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma. | |
| MX394367B (es) | Moléculas tipo esfingolípidos sintéticas, fármacos, métodos de su síntesis y usos de los mismos. | |
| CR20130693A (es) | Composición farmacéutica ortalmológica tópica que contiene regorafenib | |
| CL2011000520A1 (es) | Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos. | |
| UA107702C2 (xx) | Похідні бензаміду |